{"id":"NCT02397057","sponsor":"American Regent, Inc.","briefTitle":"Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS","officialTitle":"A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2018-01","completion":"2018-01","firstPosted":"2015-03-24","resultsPosted":"2021-10-12","lastUpdate":"2021-10-12"},"enrollment":209,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome (RLS)"],"interventions":[{"type":"DRUG","name":"Injectafer","otherNames":["Ferinject®","Iroprem®","Renegy®"]},{"type":"OTHER","name":"Placebo","otherNames":["Normal Saline"]}],"arms":[{"label":"Injectafer","type":"ACTIVE_COMPARATOR"},{"label":"Normal Saline","type":"PLACEBO_COMPARATOR"}],"summary":"This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. The subject's participation in the study will be for approximately 1 year from Day 0.","primaryOutcome":{"measure":"International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42","timeFrame":"Baseline and Day 42","effectByArm":[{"arm":"Injectafer","deltaMin":24.1,"sd":6.27},{"arm":"Normal Saline","deltaMin":24.5,"sd":6.05}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["38625730"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":107},"commonTop":["Nausea","Headache","Hypophosphataemia","Dizziness","Feeling hot"]}}